Chengdu Kangnuoxing Biopharma,inc.
Clinical trials sponsored by Chengdu Kangnuoxing Biopharma,inc., explained in plain language.
-
New injection hopes to tame tough eczema in 1,000 patients
Disease control Not yet recruitingThis study looks at how safe and effective Stapokibart injection is for adults with moderate-to-severe atopic dermatitis (eczema). About 1,000 people will take part, and their doctors have already decided to use this drug. The main goal is to track any side effects related to the…
Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated May 26, 2026 10:57 UTC
-
New injection studied for sinusitis sufferers
Disease control Not yet recruitingThis study looks at the safety of a drug called Stapokibart for people with chronic sinusitis and nasal polyps (CRSwNP). About 600 adults will receive the injection and be monitored for side effects. The goal is to check for any harmful reactions, not to cure the condition.
Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New allergy shot under safety review in 400 adults
Symptom relief Not yet recruitingThis study looks at how safe Stapokibart injection is for people with seasonal allergic rhinitis (SAR). About 400 adults will take part, and researchers will track any side effects. The goal is to see if the drug is safe enough for wider use.
Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Symptom relief
Last updated May 18, 2026 12:13 UTC